Breathe Well Live Well
Condition: Asthma
Interventions: Drug: Reslizumab; Drug: Fludeoxyglucose F 18 (FDG); Drug: Placebo
Sponsor: Teva Branded Pharmaceutical Products, R&D Inc.
Not yet recruiting – verified October 2016
View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days
|
Reslizumab improves asthma control, symptoms, lung function
Healio “Intravenous reslizumab [Cinqair, Teva Respiratory] 3.0 mg/kg provided improvements in lung function, asthma symptoms, and quality of life for patients with inadequately controlled asthma and elevated blood eosinophils (? 400 cells/µL) that were … |
View full post on asthma – Google News
Medscape |
FDA approves reslizumab to treat severe asthma
Pharmacy Today, American Pharmacists Association, pharmacist.com FDA has cleared reslizumab (Cinqair—Teva) for use with other asthma medicines for the maintenance treatment of severe asthma in adults. The drug is indicated for patients with a history of severe asthma attacks despite using their current asthma … FDA approves Cinqair to treat severe asthma Reslizumab (Cinqair) Approved to Treat Severe Asthma FDA Approves Teva's Asthma Injection to Treat Severe Asthma |
View full post on asthma – Google News
Medscape |
FDA Panel Backs Reslizumab for Adults With Severe Asthma
Medscape If approved by the FDA, it would be the third monoclonal antibody approved for asthma, after mepolizumab and omalizumab. Reslizumab binds to human interleukin-5 (IL-5). Several cytokines can affect eosinophils, but IL-5 is the main cytokine involved in … FDA experts endorse Teva's asthma drug, but reject use in key patient group FDA advisory panel recommends Teva asthma antibody FDA advisers recommend approval of Teva asthma drug in adults |
View full post on asthma – Google News
|
Reslizumab deemed safe, efficacious for treatment of asthma
Healio In a recent extension study, researchers found reslizumab was safe, efficacious and improved Asthma Quality of Life scores for up to 2 years after beginning treatment, according to data recently presented at the American College of Allergy, Asthma and … |
View full post on asthma – Google News
Market Realist |
FDA Will Review Teva's BLA for Asthma Drug Reslizumab
Market Realist Interleukin-5 is a key cytokine involved in the maturation, recruitment, and activation of eosinophils, which are inflammatory white blood cells implicated in a number of diseases, such as asthma. Elevated levels of blood eosinophils are a risk factor … |
View full post on asthma – Google News
MD Magazine |
Reslizumab Positively Impacts the Quality of Life in Severe Asthma
MD Magazine Previous phase III trials have shown that reslizumab, an investigational IgG4/k humanized monoclonal antibody, improved lung function and reduced asthma exacerbations. Now Joshua Jacobs, MD, from Allergy and Asthma Clinical Research in Walnut … |
View full post on asthma – Google News
Medscape |
Reslizumab Works Best in Late-Onset Eosinophilic Asthma
Medscape AMSTERDAM — In patients with late-onset asthma who have elevated blood eosinophils, the anti-interleukin 5 (IL-5) antibody reslizumab can reduce exacerbations by 75% compared with placebo, according to a new analysis of data from two phase 3 trials … Teva Presents New Reslizumab Data at European Respiratory Society (ERS … |
View full post on asthma – Google News
|
Cinquil (Reslizumab) (Asthma) – Forecast and Market Analysis to 2023: Research …
Medgadget.com (blog) The Report Cinquil (Reslizumab) (Asthma) – Forecast and Market Analysis to 2023 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. – MarketResearchReports.biz. GlobalData has released … |
View full post on asthma – Google News
Conditions: Asthma; Elevated Blood Eosinophils
Interventions: Drug: Reslizumab; Drug: Placebo
Sponsor: Teva Branded Pharmaceutical Products, R&D Inc.
Not yet recruiting – verified July 2015
View full post on ClinicalTrials.gov: asthma | received in the last 14 days